Physician profile
Roy Foliente
NPI 1598723348
$1,691.84
in general payments reported to CMS, 2019-2025
16 companies · $206 in 2025
The $206 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $45.89 · 2021: $14.33 · 2022: $12.29 · 2023: $758 · 2024: $656 · 2025: $206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,619.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,619.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $609.19 | 2023-2025 | |
| Janssen Biotech, INC. | $228.10 | 2023-2025 | Tremfya, Stelara |
| Boston Scientific Corporation | $211.66 | 2024-2025 | Overstitch Endoscopic Suturing System, X-Tack Endoscopic Helix Tacking System |
| Takeda Pharmaceuticals U.S.A., INC. | $208.27 | 2023-2024 | Entyvio |
| Regeneron Healthcare Solutions, INC. | $122.31 | 2023 | Dupixent |
| Pfizer INC. | $54.90 | 2024 | |
| Gilead Sciences, INC. | $44.56 | 2019-2021 | |
| Celltrion USA INC. | $38.44 | 2024 | Vegzelma |
| Celgene Corporation | $33.11 | 2023-2024 | Zeposia |
| Exact Sciences Corporation | $28.43 | 2024 | Cologuard Collection Kit |
| Genzyme Corporation | $26.56 | 2024 | |
| Madrigal Pharmaceuticals | $23.27 | 2024 | Resmetirom |
| Astrazeneca Pharmaceuticals LP | $22.28 | 2024 | Imfinzi |
| Covidien LP | $15.66 | 2019 | |
| Phathom Pharmaceuticals, INC. | $12.81 | 2023 | Voquezna |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $12.29 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roy Foliente listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.